array:19 [ "pii" => "13108884" "issn" => "18866581" "estado" => "S300" "fechaPublicacion" => "2007-04-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Apunts. Medicina de l'Esport. 2007;42:88-91" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1477 "formatos" => array:3 [ "EPUB" => 146 "HTML" => 1261 "PDF" => 70 ] ] "Traduccion" => array:1 [ "ct" => array:16 [ "pii" => "XX886658107088599" "issn" => "X8866581" "estado" => "S300" "fechaPublicacion" => "2007-04-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Apunts. Medicina de l'Esport. 2007;42:88-91" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3330 "formatos" => array:3 [ "EPUB" => 157 "HTML" => 2011 "PDF" => 1162 ] ] "ct" => array:11 [ "idiomaDefecto" => true "titulo" => "Utilitat clínica de la condroïtina sulfat" "tienePdf" => "ct" "tieneTextoCompleto" => "ct" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "88" "paginaFinal" => "91" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Clinical utility of condroitin sulfate" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "ct" => true ] "contienePdf" => array:1 [ "ct" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Josep Vergés" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Josep" "apellidos" => "Vergés" ] ] ] ] ] "idiomaDefecto" => "ct" "Traduccion" => array:2 [ "en" => array:8 [ "pii" => "13108884" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108884?idApp=UINPBA00004N" ] "es" => array:8 [ "pii" => "X0213371707088843" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0213371707088843?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088599?idApp=UINPBA00004N" "url" => "/X8866581/0000004200000154/v0_201801081416/XX886658107088599/v0_201801081416/ct/main.assets" ] ] "itemSiguiente" => array:16 [ "pii" => "13108885" "issn" => "18866581" "estado" => "S300" "fechaPublicacion" => "2007-04-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Apunts. Medicina de l'Esport. 2007;42:92-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2123 "formatos" => array:3 [ "EPUB" => 149 "HTML" => 1857 "PDF" => 117 ] ] "en" => array:7 [ "idiomaDefecto" => true "titulo" => "Sports activity and bone mass (II). The characteristics of physical activity that affect bone formation" "tieneTextoCompleto" => 0 "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "92" "paginaFinal" => "98" ] ] "contieneResumen" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Caritat Bagur Calafat" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Caritat" "apellidos" => "Bagur Calafat" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "ct" => array:8 [ "pii" => "XX886658107088603" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "ct" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088603?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108885?idApp=UINPBA00004N" "url" => "/18866581/0000004200000154/v0_201801081334/13108885/v0_201801081334/en/main.assets" ] "itemAnterior" => array:16 [ "pii" => "13108883" "issn" => "18866581" "estado" => "S300" "fechaPublicacion" => "2007-04-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Apunts. Medicina de l'Esport. 2007;42:82-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1700 "formatos" => array:3 [ "EPUB" => 129 "HTML" => 1439 "PDF" => 132 ] ] "en" => array:7 [ "idiomaDefecto" => true "titulo" => "Evaluation of useful force in tennis" "tieneTextoCompleto" => 0 "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "82" "paginaFinal" => "87" ] ] "contieneResumen" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Raúl Pablo Garrido Chamorro, Cristina Blasco Lafarga, Alejandro Ricardo Albert Giménez,  Emilio José Poveda Pagán, Jesús Mas Martínez" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Raúl Pablo" "apellidos" => "Garrido Chamorro" ] 1 => array:2 [ "nombre" => "Cristina" "apellidos" => "Blasco Lafarga" ] 2 => array:2 [ "nombre" => "Alejandro Ricardo" "apellidos" => "Albert Giménez" ] 3 => array:2 [ "nombre" => " Emilio José" "apellidos" => "Poveda Pagán" ] 4 => array:2 [ "nombre" => "Jesús" "apellidos" => "Mas Martínez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "ct" => array:8 [ "pii" => "XX886658107088580" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "ct" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088580?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108883?idApp=UINPBA00004N" "url" => "/18866581/0000004200000154/v0_201801081334/13108883/v0_201801081334/en/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Clinical utility of condroitin sulfate" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "88" "paginaFinal" => "91" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Josep Vergés" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Josep" "apellidos" => "Vergés" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Falcultat de Medicina. Universidad Autónoma de Madrid. Madrid. España." "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "tienePdf" => false "tieneResumen" => true "resumen" => array:1 [ "en" => array:1 [ "resumen" => "<span class="elsevierStyleBold">Introduction:</span> Chondroitin sulfate belongs to the group of symptomatic slow-acting drugs for osteoarthritis (SYSADOA). The efficacy of this drug on symptoms is similar to that of non-steroidal anti-inflammatory agents, the effect starting gradually but persisting after treatment suppression. <span class="elsevierStyleBold">Materials and methods:</span> We analyzed randomized, double-blind clinical trials that compared the effect of chondroitin sulfate with that placebo and, in one trial, with sodium diclofenac (150 mg/day) in patients with knee and finger osteoarthritis treated for periods ranging from 3 to 36 months. <span class="elsevierStyleBold">Results:</span> The results of all the clinical trials indicate that chondroitin sulfate is more effective (by approximately 50%, p < 0.05) than placebo in reducing spontaneous pain, increasing joint function, and reducing rescue medication; in addition overall patient and physician assessment was higher. Equally, the trials confirm the high safety profile of the drug. A new clinical trial conducted in 1,583 patients with knee osteoarthritis, which studied the effect of glucosamine (1,500 mg /day), chondroitin sulfate (1,200 mg /day) and their association in comparison with celecoxib (200 mg/ day) and placebo for 6 months found a significant reduction of joint swelling, with or without joint effusion, for the chondroitin sulfate group compared with the placebo group (p = 0.01). <span class="elsevierStyleBold">Conclusion:</span> Chondroitin sulfate is a highly useful therapeutic tool for the treatment of osteoarthritis." ] ] ] "idiomaDefecto" => "en" "url" => "/18866581/0000004200000154/v0_201801081334/13108884/v0_201801081334/en/main.assets" "Apartado" => array:4 [ "identificador" => "71845" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108884?idApp=UINPBA00004N" ]
Journal Information
Vol. 42. Issue 154.
Pages 88-91 (April 2007)
Vol. 42. Issue 154.
Pages 88-91 (April 2007)
Full text access
Clinical utility of condroitin sulfate
Visits
1052
This item has received
Article information
Abstract
Statistics
Introduction: Chondroitin sulfate belongs to the group of symptomatic slow-acting drugs for osteoarthritis (SYSADOA). The efficacy of this drug on symptoms is similar to that of non-steroidal anti-inflammatory agents, the effect starting gradually but persisting after treatment suppression. Materials and methods: We analyzed randomized, double-blind clinical trials that compared the effect of chondroitin sulfate with that placebo and, in one trial, with sodium diclofenac (150 mg/day) in patients with knee and finger osteoarthritis treated for periods ranging from 3 to 36 months. Results: The results of all the clinical trials indicate that chondroitin sulfate is more effective (by approximately 50%, p < 0.05) than placebo in reducing spontaneous pain, increasing joint function, and reducing rescue medication; in addition overall patient and physician assessment was higher. Equally, the trials confirm the high safety profile of the drug. A new clinical trial conducted in 1,583 patients with knee osteoarthritis, which studied the effect of glucosamine (1,500 mg /day), chondroitin sulfate (1,200 mg /day) and their association in comparison with celecoxib (200 mg/ day) and placebo for 6 months found a significant reduction of joint swelling, with or without joint effusion, for the chondroitin sulfate group compared with the placebo group (p = 0.01). Conclusion: Chondroitin sulfate is a highly useful therapeutic tool for the treatment of osteoarthritis.